加贝脂对ERCP患者十二指肠乳头局部组织中VIP和nNOS表达的影响  

Pretreatment with gabexate mesilate alters expression of vasoactive intestinal peptide and neuronal nitric oxide synthase in the duodenal mucosa of patients undergoing ERCP

作　　者：郭志国[1] 韩真[1] 袁鹤鸣[1] 

机构地区：[1]皖南医学院弋矶山医院消化内科,安徽省芜湖市241001

出　　处：《世界华人消化杂志》2011年第16期1731-1734,共4页World Chinese Journal of Digestology

摘　　要：目的:探讨加贝脂在内镜逆行胰胆管造影术(ERCP)患者十二指肠乳头黏膜、括约肌组织中血管活性肠肽(VIP)和神经型一氧化氮合酶(nNOS)含量的影响.方法:选择2009-09/2010-07因不明原因的上腹痛、黄疸到皖南医学院弋矶山医院就诊患者,在签署知情同意书后接受逆行胰胆造影术,共30例.按随机双盲法分成加贝酯组(GM组)与对照组.GM组静脉滴注加贝酯100mg+0.9%生理盐水100mL以2.5mg/(kg?h)速度静脉滴入,输液结束后3min取材;对照组给予0.9%生理盐水100mL静滴,取材同前.标本常规置于-70℃冰箱保存,采用双抗体两步夹心ELISA测定组织内VIP及nNOS含量的变化.结果:GM组十二指肠乳头黏膜中VIP(ng/L)显著高于对照组(0.032±0.004vs0.031±0.002,P<0.05),nNOS值较对照组无显著性差异;GM组Oddi括约肌中VIP较对照组无明显差异,而nNOS(μmol/L)较对照组差异非常显著(9.55±1.10vs8.29±0.56,P<0.01).结论:应用常规剂量的GM患者十二指肠乳头黏膜中VIP的含量增加,Oddi括约肌中nNOS的含量明显增加.AIM： To explore the effect of pretreatment with gabexate mesilate on the expression of vasoactive intestinal peptide （VIP） and neuronal nitric oxide synthase （nNOS） in the duodenal mucosa of patients undergoing endoscopic retrograde cholangiopancreatography （ERCP）. METHODS： A total of thirty patients with unexplained abdominal pain and jaundice were recruited to the study from September 2009 to July 2010 and divided into two groups： patients intravenously infused with gabexate mesilate and those with saline before ERCP. Three minutes after infusion, specimens were taken to detect the levels of VIP and nNOS by means of double-antibody sandwich ELISA. RESULTS： The level of VIP （ng/L） in the papillary mucosa of patients pretreated with gabexate mesilate was significantly higher than that of controls （0.032 ± 0.004 vs 0.031 ± 0.002, P 0.05）, while that of nNOS showed no statistical difference between the two groups of patients. The mean content of nNOS （μmol/L） in the sphincter of Oddi of patients pretreated with gabexate mesilate was signifi cantly higher than that of controls （9.55 ± 1.10 vs 8.29 ± 0.56, P 0.01）, while there was no marked difference in the level of nNOS in the sphincter of Oddi between the two groups of patients. CONCLUSION： Pretreatment with gabexate mesilate up-regulates the expression of VIP in the papillary mucosa and nNOS in the sphincter of Oddi in patients undergoing ERCP.

关 键 词：加贝脂 ODDI括约肌 血管活性肠肽 神经型一氧化氮合酶 

分 类 号：R576[医药卫生—消化系统]